Literature DB >> 32055842

Exploration of databases and methods supporting drug repurposing: a comprehensive survey.

Ziaurrehman Tanoli1, Umair Seemab2, Andreas Scherer1, Krister Wennerberg3, Jing Tang4, Markus Vähä-Koskela1.   

Abstract

Drug development involves a deep understanding of the mechanisms of action and possible side effects of each drug, and sometimes results in the identification of new and unexpected uses for drugs, termed as drug repurposing. Both in case of serendipitous observations and systematic mechanistic explorations, confirmation of new indications for a drug requires hypothesis building around relevant drug-related data, such as molecular targets involved, and patient and cellular responses. These datasets are available in public repositories, but apart from sifting through the sheer amount of data imposing computational bottleneck, a major challenge is the difficulty in selecting which databases to use from an increasingly large number of available databases. The database selection is made harder by the lack of an overview of the types of data offered in each database. In order to alleviate these problems and to guide the end user through the drug repurposing efforts, we provide here a survey of 102 of the most promising and drug-relevant databases reported to date. We summarize the target coverage and types of data available in each database and provide several examples of how multi-database exploration can facilitate drug repurposing.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  biomolecular databases; disease databases; drug databases; drug repositioning; drug–target interaction databases

Year:  2021        PMID: 32055842     DOI: 10.1093/bib/bbaa003

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  14 in total

1.  Using BERT to identify drug-target interactions from whole PubMed.

Authors:  Jehad Aldahdooh; Markus Vähä-Koskela; Jing Tang; Ziaurrehman Tanoli
Journal:  BMC Bioinformatics       Date:  2022-06-21       Impact factor: 3.307

Review 2.  Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs.

Authors:  Neda Eskandarzade; Abozar Ghorbani; Samira Samarfard; Jose Diaz; Pietro H Guzzi; Niloofar Fariborzi; Ahmad Tahmasebi; Keramatollah Izadpanah
Journal:  Comput Biol Med       Date:  2022-04-30       Impact factor: 6.698

3.  Reconciling multiple connectivity scores for drug repurposing.

Authors:  Kewalin Samart; Phoebe Tuyishime; Arjun Krishnan; Janani Ravi
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

Review 4.  Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.

Authors:  Hyung Muk Choi; Soo Youn Moon; Hyung In Yang; Kyoung Soo Kim
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

5.  LigAdvisor: a versatile and user-friendly web-platform for drug design.

Authors:  Luca Pinzi; Annachiara Tinivella; Luca Gagliardelli; Domenico Beneventano; Giulio Rastelli
Journal:  Nucleic Acids Res       Date:  2021-07-02       Impact factor: 16.971

Review 6.  Virtual Combinatorial Chemistry and Pharmacological Screening: A Short Guide to Drug Design.

Authors:  Beatriz Suay-García; Jose I Bueso-Bordils; Antonio Falcó; Gerardo M Antón-Fos; Pedro A Alemán-López
Journal:  Int J Mol Sci       Date:  2022-01-30       Impact factor: 5.923

Review 7.  Computational analyses of mechanism of action (MoA): data, methods and integration.

Authors:  Maria-Anna Trapotsi; Layla Hosseini-Gerami; Andreas Bender
Journal:  RSC Chem Biol       Date:  2021-12-22

8.  Research on the potential mechanism of Chuanxiong Rhizoma on treating Diabetic Nephropathy based on network pharmacology.

Authors:  Shanshan Hu; Siteng Chen; Zhilei Li; Yuhang Wang; Yong Wang
Journal:  Int J Med Sci       Date:  2020-08-21       Impact factor: 3.738

Review 9.  Alternative strategies in cardiac preclinical research and new clinical trial formats.

Authors:  Fabian Philipp Kreutzer; Anna Meinecke; Kevin Schmidt; Jan Fiedler; Thomas Thum
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

10.  Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments.

Authors:  Ziaurrehman Tanoli; Jehad Aldahdooh; Farhan Alam; Yinyin Wang; Umair Seemab; Maddalena Fratelli; Petr Pavlis; Marian Hajduch; Florence Bietrix; Philip Gribbon; Andrea Zaliani; Matthew D Hall; Min Shen; Kyle Brimacombe; Evgeny Kulesskiy; Jani Saarela; Krister Wennerberg; Markus Vähä-Koskela; Jing Tang
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.